房颤患者经皮冠状动脉介入后抗栓策略的个体数据网络荟萃分析
对6项随机试验共10634例接受经皮冠状动脉介入治疗的房颤患者进行个体数据网络荟萃分析,比较DOAC联合P2Y12抑制剂、VKA联合单药抗血小板、VKA联合双联抗血小板及DOAC联合双联抗血小板四种策略。结果显示各策略在心血管死亡、心肌梗死或卒中的复合终点上无显著差异,但DOAC联合P2Y12抑制剂较VKA联合双联抗血小板显著减少TIMI大出血和颅内出血。
要点
- DOAC联合P2Y12抑制剂与VKA联合双联抗血小板相比,缺血事件风险无显著差异。
- DOAC方案较VKA方案显著降低TIMI大出血及颅内出血风险。
- 术后14天内单药抗血小板方案心肌梗死和支架血栓风险增高。
核心结论
- 在房颤患者经皮冠状动脉介入治疗后,使用DOAC或VKA的心血管死亡、心肌梗死或卒中风险无显著差异。
- DOAC相比VKA可降低各级出血风险,包括颅内出血。
- 与双联抗血小板相比,单药抗血小板方案的早期冠状动脉事件风险有轻度增加可能。
研究设计与样本
- 本研究为基于随机试验个体患者数据的网络荟萃分析,纳入6项试验共10634例房颤接受经皮冠状动脉介入治疗的患者。
- 采用按试验分层的Cox比例风险模型估计风险比及95%置信区间。
- 研究已在PROSPERO注册,注册号为CRD420251130025。
主要发现
- 1年时主要疗效终点在各抗栓策略间无显著差异,DOAC联合P2Y12抑制剂、VKA联合单药抗血小板、DOAC联合双联抗血小板相对于VKA联合双联抗血小板的风险比分别为1.16(95%CI 0.97-1.41)、1.14(95%CI 0.85-1.54)和0.99(95%CI 0.75-1.30)。
- 14天界标分析显示,DOAC联合P2Y12抑制剂或VKA联合单药抗血小板在PCI术后早期心肌梗死和明确或可能的支架血栓风险增高。
- DOAC联合P2Y12抑制剂与VKA联合双联抗血小板相比,主要安全性终点风险比为0.48(95%CI 0.38-0.65);与VKA联合单药抗血小板相比为0.62(95%CI 0.40-0.97);与DOAC联合双联抗血小板相比为0.66(95%CI 0.44-1.01)。
- DOAC联合P2Y12抑制剂与VKA联合双联抗血小板相比,颅内出血风险比为0.21(95%CI 0.07-0.64)。
临床怎么用
- 抗栓策略的选择在缺血终点方面未见显著差异,出血风险应作为方案选择的重要考量。
- PCI术后早期应警惕单药抗血小板策略相关的心肌梗死和支架血栓风险。
- DOAC联合P2Y12抑制剂可作为减少出血风险且不增加缺血事件的选择。
局限性
- 单药与双联抗血小板相比的早期冠状动脉事件风险增加不能完全排除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Randomized trials demonstrated that in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) direct oral anticoagulants (DOAC) and a P2Y12 inhibitor reduce bleeding compared with vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT) with no increase in ischemic risk; however, important gaps in knowledge remain, limiting certainty and generalizability of these findings. METHODS: In this patient-level meta-analysis of randomized trials evaluating antithrombotic strategies in patients with AF undergoing PCI, Cox proportional hazard models, stratified by trial, were used to estimate hazard ratios and 95% confidence intervals (HR, 95%CI). The primary efficacy and safety outcomes were the composite of cardiovascular death, myocardial infarction, or stroke, and TIMI major bleeding, respectively. The study was registered in PROSPERO (CRD420251130025). RESULTS: Six trials (10,634 patients) comparing DOAC plus P2Y12 inhibitor (4,083), VKA plus single antiplatelet therapy (SAPT, 1,247), VKA plus DAPT (3,715), and DOAC plus DAPT (1,589) were included. The transition from DAPT to SAPT was recommended at 1 (1-3) and 3 (1-7) days in the DOAC plus P2Y12 inhibitor and VKA plus SAPT groups, respectively. At 1 year, the risk of the primary efficacy outcome did not differ across the antithrombotic strategies (reference group: VKA plus DAPT; DOAC plus P2Y12 inhibitor: HR 1.16, 95%CI 0.97-1.41; VKA plus SAPT: 1.14, 0.85-1.54, DOAC plus DAPT: 0.99, 0.75-1.30), without any statistically significant interaction between treatment effects and all prespecified subgroups, including age, sex, bleeding risk, and thrombotic risk. However, 14-day landmark analysis showed an increased risk of myocardial infarction and definite/probable stent thrombosis in patients receiving DOAC plus P2Y12 inhibitor or VKA plus SAPT in the early phase after PCI. DOAC plus P2Y12 inhibitor reduced the risk of the primary safety outcome compared with VKA plus DAPT (0.48, 0.38- 0.65) and VKA plus SAPT (0.62, 0.40-0.97); only a borderline reduction was observed compared to DOAC plus DAPT (0.66, 0.44-1.01). DOAC plus P2Y12 inhibitor reduced intracranial hemorrhage compared with VKA plus DAPT (0.21, 0.07-0.64). CONCLUSIONS: In patients with AF undergoing PCI, the risk of cardiovascular death, myocardial infarction, or stroke did not significantly differ according to whether patients received a DOAC or VKA, whereas a modest increase in risk with single compared with dual antiplatelet therapy cannot be excluded, given the higher risk of early coronary events. DOACs compared with VKAs reduced the risk of bleeding across all severity grades, including intracranial hemorrhage, whereas omission of a second antiplatelet agent reduced the risk of TIMI major or minor bleeding.
引用
- Chiarito, Mehran, Gibson, et al. Antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation: an individual patient data network meta-analysis. Eur Heart J. 2026. PMID: 42669062. doi:10.1093/eurheartj/ehag740
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。